Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 10 (October)

1. Mammographic screening for young women with a family history of breast cancer: knowledge and views of those at risk.
   Br J Cancer, 99(7): 1007-12. [Abstract] [Full-text]
2. Transplantation in identical twins: another option for breast reconstruction.
   Plast Reconstr Surg, 122(4): 1019-23. [Abstract] [Full-text]
3. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer.
   Br J Cancer, 99(7): 1013-9. [Abstract] [Full-text]
4. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.
   Br J Cancer, 99(7): 1056-63. [Abstract] [Full-text]
5. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
   Br J Cancer, 99(7): 1089-95. [Abstract] [Full-text]
6. Determinants of the number of mammography units in 31 countries with significant mammography screening.
   Br J Cancer, 99(7): 1185-90. [Abstract] [Full-text]
7. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.
   Br J Cancer, 99(7): 1000-6. [Abstract] [Full-text]
8. Complexities in the estimation of overdiagnosis in breast cancer screening.
   Br J Cancer, 99(7): 1176-8. [Abstract] [Full-text]
9. Dietary glycaemic index, glycaemic load and breast cancer risk: a systematic review and meta-analysis.
   Br J Cancer, 99(7): 1170-5. [Abstract] [Full-text]
10. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis.
    J Natl Cancer Inst, 100(19): 1352-60. [Abstract] [Full-text]
11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    J Natl Cancer Inst, 100(19): 1380-8. [Abstract] [Full-text]
12. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
    J Natl Cancer Inst, 100(19): 1361-7. [Abstract] [Full-text]
13. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.
    Proc Natl Acad Sci U S A, 105(39): 14867-72. [Abstract] [Full-text]
14. New pathway links from cancer-progression determinants to gene expression of matrix metalloproteinases in breast cancer cells.
    J Cell Physiol, 217(3): 739-44. [Abstract] [Full-text]
15. Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol.
    Cancer Chemother Pharmacol, 63(1): 27-35. [Abstract] [Full-text]
16. Non-compliance with a postmastectomy radiotherapy guideline: decision tree and cause analysis.
    BMC Med Inform Decis Mak, 8: 41. [Abstract] [Full-text]
17. Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study.
    Carcinogenesis, 29(10): 1967-72. [Abstract] [Full-text]
18. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
    Carcinogenesis, 29(10): 1963-6. [Abstract] [Full-text]
19. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules.
    Carcinogenesis, 29(10): 1885-92. [Abstract] [Full-text]
20. Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study.
    Carcinogenesis, 29(10): 1944-9. [Abstract] [Full-text]
21. Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals.
    Carcinogenesis, 29(10): 1862-8. [Abstract] [Full-text]
22. Concomitant presence of mutations in mitochondrial genome and p53 in cancer development - a study in north Indian sporadic breast and esophageal cancer patients.
    Int J Cancer, 123(11): 2580-6. [Abstract] [Full-text]
23. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis.
    Int J Cancer, 123(11): 2518-31. [Abstract] [Full-text]
24. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.
    Int J Cancer, 123(11): 2713-6. [Abstract] [Full-text]
25. How does age affect baseline screening mammography performance measures? A decision model.
    BMC Med Inform Decis Mak, 8: 40. [Abstract] [Full-text]
26. Cavernous hemangioma in the axillary region mimicking malignant neoplasia.
    South Med J, 101(10): 1051-3. [Abstract] [Full-text]
27. Rare case of breast tumor secondary to rectal adenocarcinoma.
    South Med J, 101(10): 1062-4. [Abstract] [Full-text]
28. Racial segregation and disparities in breast cancer care and mortality.
    Cancer, 113(8): 2166-72. [Abstract] [Full-text]
29. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer.
    Cancer, 113(8): 2011-9. [Abstract] [Full-text]
30. Performance of BRCA1/2 mutation prediction models in Asian Americans.
    J Clin Oncol, 26(29): 4752-8. [Abstract] [Full-text]
31. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    J Clin Oncol, 26(29): 4739-45. [Abstract] [Full-text]
32. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    J Clin Oncol, 26(29): 4746-51. [Abstract] [Full-text]
33. Identification of a dietary pattern characterized by high-fat food choices associated with increased risk of breast cancer: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.
    Br J Nutr, 100(5): 942-6. [Abstract] [Full-text]
34. Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer.
    Am J Epidemiol, 168(8): 915-24. [Abstract] [Full-text]
35. The use of radioisotope combined with isosulfan Blue dye is not superior to radioisotope alone for the identification of sentinel lymph nodes in patients with breast cancer.
    Surgery, 144(4): 606-9; discussion 609-10. [Abstract] [Full-text]
36. Optimal number of radioactive sentinel lymph nodes to remove for accurate axillary staging of breast cancer.
    Surgery, 144(4): 525-31; discussion 531-2. [Abstract] [Full-text]
37. Histopathologic characteristics of the primary tumor in breast cancer patients with isolated tumor cells of the sentinel node.
    Surgery, 144(4): 518-24; discussion 524. [Abstract] [Full-text]
38. Actein inhibits the Na+-K+-ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells.
    Biochem Biophys Res Commun, 375(4): 608-13. [Abstract] [Full-text]
39. Technical developments in mammography.
    Health Phys, 95(5): 599-611. [Abstract] [Full-text]
40. Prevalence and characteristics of the MMTV-like associated breast carcinomas in Tunisia.
    Cancer Lett, 271(2): 222-30. [Abstract] [Full-text]
41. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.
    Genes Chromosomes Cancer, 47(12): 1049-66. [Abstract] [Full-text]
42. Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer.
    Genes Chromosomes Cancer, 47(12): 1098-109. [Abstract] [Full-text]
43. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care.
    Arch Intern Med, 168(18): 2033-40. [Abstract] [Full-text]
44. Caffeine consumption and the risk of breast cancer in a large prospective cohort of women.
    Arch Intern Med, 168(18): 2022-31. [Abstract] [Full-text]
45. Recommendation for and receipt of cancer screenings among medicaid recipients 50 years and older.
    Arch Intern Med, 168(18): 2014-21. [Abstract] [Full-text]
46. TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.
    BMC Cancer, 8: 282. [Abstract] [Full-text]
47. U-statistics-based tests for multiple genes in genetic association studies.
    Ann Hum Genet, 72: 821-33. [Abstract] [Full-text]
48. CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma.
    Am J Clin Pathol, 130(5): 724-30. [Abstract] [Full-text]
49. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer.
    J Natl Cancer Inst, 100(20): 1448-53. [Abstract] [Full-text]
50. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis.
    J Natl Cancer Inst, 100(20): 1439-47. [Abstract] [Full-text]
51. Prospective evaluation of risk factors for male breast cancer.
    J Natl Cancer Inst, 100(20): 1477-81. [Abstract] [Full-text]
52. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    BMC Cancer, 8: 286. [Abstract] [Full-text]
53. TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival.
    Br J Cancer, 99(8): 1357-63. [Abstract] [Full-text]
54. Adiponectin differentially affects gene expression in human mammary epithelial and breast cancer cells.
    Br J Cancer, 99(8): 1246-50. [Abstract] [Full-text]
55. Breast cancer awareness among older women.
    Br J Cancer, 99(8): 1221-5. [Abstract] [Full-text]
56. NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life.
    Br J Cancer, 99(8): 1226-31. [Abstract] [Full-text]
57. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
    Mol Cell Biol, 28(21): 6580-93. [Abstract] [Full-text]
58. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Mol Cancer Res, 6(10): 1630-8. [Abstract] [Full-text]
59. Single reading with computer-aided detection for screening mammography.
    N Engl J Med, 359(16): 1675-84. [Abstract] [Full-text]
60. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.
    Oncogene, 27(47): 6151-63. [Abstract] [Full-text]
61. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.
    Oncogene, 27(47): 6120-30. [Abstract] [Full-text]
62. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer.
    Cancer Res, 68(20): 8499-506. [Abstract] [Full-text]
63. Nicotine promotes mammary tumor migration via a signaling cascade involving protein kinase C and CDC42.
    Cancer Res, 68(20): 8473-81. [Abstract] [Full-text]
64. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.
    Cancer Res, 68(20): 8400-9. [Abstract] [Full-text]
65. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells.
    Cancer Res, 68(20): 8295-303. [Abstract] [Full-text]
66. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
    Cancer Res, 68(20): 8286-94. [Abstract] [Full-text]
67. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer.
    Cancer Res, 68(20): 8201-9. [Abstract] [Full-text]
68. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.
    BMC Cancer, 8: 287. [Abstract] [Full-text]
69. Growth suppression of MCF-7 cancer cell-derived xenografts in nude mice by caveolin-1.
    Biochem Biophys Res Commun, 376(1): 215-20. [Abstract] [Full-text]
70. Mammographic features and histopathological findings of interval breast cancers.
    Acta Radiol, 49(9): 975-81. [Abstract] [Full-text]
71. Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.
    J Med Chem, 51(20): 6256-8. [Abstract] [Full-text]
72. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    J Clin Oncol, 26(30): 4869-74. [Abstract] [Full-text]
73. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
    J Clin Oncol, 26(30): 4883-90. [Abstract] [Full-text]
74. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
    J Clin Oncol, 26(30): 4899-905. [Abstract] [Full-text]
75. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
    J Clin Oncol, 26(30): 4891-8. [Abstract] [Full-text]
76. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    J Clin Oncol, 26(30): 4875-82. [Abstract] [Full-text]
77. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review.
    J Clin Oncol, 26(30): 4981-9. [Abstract] [Full-text]
78. Patterns of DNA copy number changes in sentinel lymph node breast cancer metastases.
    Cytogenet Genome Res, 122(1): 16-21. [Abstract] [Full-text]
79. Glucuronidation of the soyabean isoflavones genistein and daidzein by human liver is related to levels of UGT1A1 and UGT1A9 activity and alters isoflavone response in the MCF-7 human breast cancer cell line.
    J Nutr Biochem, 19(11): 739-45. [Abstract] [Full-text]
80. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53.
    Cancer Lett, 271(1): 64-80. [Abstract] [Full-text]
81. Mammography screening among Arab American women in metropolitan Detroit.
    J Immigr Minor Health, 10(6): 541-9. [Abstract] [Full-text]
82. Suspicious breast lesions: assessment of 3D Doppler US indexes for classification in a test population and fourfold cross-validation scheme.
    Radiology, 249(2): 463-70. [Abstract] [Full-text]
83. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings--preliminary results.
    Radiology, 249(2): 471-82. [Abstract] [Full-text]
84. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors.
    Hum Mol Genet, 17(22): 3596-600. [Abstract] [Full-text]
85. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer.
    Mol Pharmacol, 74(5): 1359-66. [Abstract] [Full-text]
86. Continuous in vitro exposure to low-dose genistein induces genomic instability in breast epithelial cells.
    Cancer Genet Cytogenet, 186(2): 78-84. [Abstract] [Full-text]
87. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.
    Proc Natl Acad Sci U S A, 105(42): 16224-9. [Abstract] [Full-text]
88. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Proc Natl Acad Sci U S A, 105(42): 16254-9. [Abstract] [Full-text]
89. Amplification of HER2 is a marker for global genomic instability.
    BMC Cancer, 8: 297. [Abstract] [Full-text]
90. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
    Am J Pathol, 173(5): 1551-65. [Abstract] [Full-text]
91. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
    Am J Pathol, 173(5): 1540-50. [Abstract] [Full-text]
92. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.
    Ann Oncol, 19(11): 1870-4. [Abstract] [Full-text]
93. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
    Ann Oncol, 19(11): 1860-9. [Abstract] [Full-text]
94. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
    Ann Oncol, 19(11): 1853-9. [Abstract] [Full-text]
95. Platinum-based chemotherapy in triple-negative breast cancer.
    Ann Oncol, 19(11): 1847-52. [Abstract] [Full-text]
96. Axillary recurrence in sentinel lymph node-negative breast cancer patients.
    Ann Oncol, 19(11): 1842-6. [Abstract] [Full-text]
97. Impact of physician-patient discussions on patient satisfaction.
    Med Care, 46(11): 1157-62. [Abstract] [Full-text]
98. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression.
    Mol Cell Biol, 28(22): 6731-45. [Abstract] [Full-text]
99. Value of intraoperative examination of axillary sentinel nodes in carcinoma of the breast.
    J Am Coll Surg, 207(5): 758-62. [Abstract] [Full-text]
100. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
     Am J Surg Pathol, 32(11): 1721-6. [Abstract] [Full-text]
101. Aromatase inhibitors in the management of early breast cancer.
     Eur J Surg Oncol, 34(11): 1199-207. [Abstract] [Full-text]
102. The value of quality of life and health status measurements in the evaluation of the well-being of breast cancer survivors.
     Eur J Surg Oncol, 34(11): 1225-30. [Abstract] [Full-text]
103. Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy.
     Int J Radiat Oncol Biol Phys, 72(4): 1016-20. [Abstract] [Full-text]
104. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer.
     Int J Radiat Oncol Biol Phys, 72(4): 1056-63. [Abstract] [Full-text]
105. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study.
     Int J Radiat Oncol Biol Phys, 72(4): 1021-30. [Abstract] [Full-text]
106. QSAR model for alignment-free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP-lattice networks.
     J Comput Chem, 29(16): 2613-22. [Abstract] [Full-text]
107. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis.
     Int J Radiat Oncol Biol Phys, 72(4): 1031-40. [Abstract] [Full-text]
108. When is CT-based postoperative seroma most useful to plan partial breast radiotherapy? Evaluation of clinical factors affecting seroma volume and clarity.
     Int J Radiat Oncol Biol Phys, 72(4): 1064-9. [Abstract] [Full-text]
109. Is a short-interval postradiation mammogram necessary after conservative surgery and radiation in breast cancer?
     Int J Radiat Oncol Biol Phys, 72(4): 1041-7. [Abstract] [Full-text]
110. Tumor location, interval between surgery and radiotherapy, and boost technique influence local control after breast-conserving surgery and radiation: retrospective analysis of monoinstitutional long-term results.
     Int J Radiat Oncol Biol Phys, 72(4): 1048-55. [Abstract] [Full-text]
111. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
     RNA, 14(11): 2348-60. [Abstract] [Full-text]
112. Liquid-based fluorescence in situ hybridization assay for detection of ERBB2 gene amplification in patients with breast cancer.
     Clin Chem, 54(11): 1831-9. [Abstract] [Full-text]
113. Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy.
     Oncology, 75(3): 237-44. [Abstract] [Full-text]
114. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings.
     Oncology, 75(3): 192-202. [Abstract] [Full-text]
115. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
     Oncology, 75(3): 175-81. [Abstract] [Full-text]
116. High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.
     BMC Cancer, 8: 288. [Abstract] [Full-text]
117. Cost-effectiveness of breast cancer screening in women on dialysis.
     Am J Kidney Dis, 52(5): 916-29. [Abstract] [Full-text]
118. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.
     J Clin Oncol, 26(31): 5022-6. [Abstract] [Full-text]
119. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
     J Clin Oncol, 26(31): 5027-35. [Abstract] [Full-text]
120. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
     J Clin Oncol, 26(31): 5036-42. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.